Pfizer’s Paxlovid Misses On Prevention, But Impact Limited
A Phase II/III trial testing Paxlovid as a preventative treatment for COVID-19 failed to show a statistically significant efficacy benefit.
You may also be interested in...
Access to the COVID-19 treatment is broadening, but Pfizer says there is still work to do when it comes to getting the antiviral to patients quickly.
The company could reach $100bn in revenues in 2022 for the first time, powered by Comirnaty and Paxlovid; actual sales for the COVID-19 products are likely to go higher based on supply contracts.
In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.